ArticlePloS one2026
Combined effect of metabolic syndrome and cancer on depression.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer survivors frequently experience depression and metabolic dysfunction; however, the combined impact of these conditions remains understudied.
aimThis study aimed to examine the joint associations between cancer, metabolic syndrome, and depression.
methodsData from the 2007-2021 Korea National Health and Nutrition Examination Survey encompassed 57,176 participants aged ≥ 19 years. Cancer diagnosis and components of metabolic syndrome (waist circumference, triglycerides, high-density lipoprotein cholesterol, blood pressure, and fasting glucose) were obtained through self-report or clinical measurement. Depression was assessed using a single-item question regarding persistent sadness or hopelessness. Multivariable logistic regression models evaluated the associations among cancer, metabolic syndrome, and depression, adjusting for sociodemographic and lifestyle factors.
resultsAmong participants, 1,691 (3.0%) had cancer, 17,510 (30.7%) met criteria for metabolic syndrome, and 7,472 (13.1%) reported depression. Cancer was independently associated with increased risk of depression (odds ratio: 1.26; 95% confidence interval: 1.10-1.45). While metabolic syndrome alone was not significantly associated with depression, patients with cancer who had elevated triglycerides (≥ 150 mg/dL) or decreased high-density lipoprotein cholesterol exhibited substantially higher risk of depression (odds ratio: 1.51; 95% confidence interval: 1.17-1.95 and odds ratio: 1.32; 95% confidence interval: 1.07-1.62, respectively). The association between elevated triglycerides in cancer survivors and depression remained robust after FDR correction.
conclusionsSpecific lipid abnormalities, rather than metabolic syndrome as a whole, were significantly associated with a higher prevalence of depression among cancer survivors. These findings underscore the need for integrated screening and management that address both metabolic dysfunction and mental health in cancer survivorship care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.